Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 9:8:427.
doi: 10.3389/fonc.2018.00427. eCollection 2018.

Second Primary Lung Cancer After Breast Cancer: A Population-Based Study of 6,269 Women

Rong Wang  1 , Zhiqiang Yin  2 , Lingxiang Liu  1 , Wen Gao  1 , Wei Li  1 , Yongqian Shu  1 , Jiali Xu  1
Affiliations

Second Primary Lung Cancer After Breast Cancer: A Population-Based Study of 6,269 Women

Rong Wang et al. Front Oncol. .

Abstract

Purpose: Breast cancer (BC) and lung cancer are the most two common cancers with highest morbidity and mortality for women. With prolonged survival, there comes the possibility that BC patients will develop second primary cancers. We evaluate the characteristics, incidence and survival of second primary non-small cell lung cancer (BC-NSCLC) and small cell lung cancer (BC-SCLC) after breast cancer. Patients and methods: Second primary lung cancer risks using standardized incidence ratios (SIRs) [95% confidence intervals (95% CIs)] were calculated among breast cancer patients in SEER-18 (2000-2014). Survival outcomes were also analyzed for both BC-NSCLC and BC-SCLC. Results: A total of 6,269 second lung cancer patients after a localized or regional BC were identified. The incidence rate was modestly higher compared to the general population (SIR = 1.03; 95%CI: 1.00-1.06). For ER-, PR- and HER2- groups, SIRs were 1.26, 1.16, 1.13, respectively (all p < 0.05). Triple negative breast cancer (TNBC) patients have an even higher incidence rate of lung cancer (SIR = 1.59, 95%CI: 1.29-1.94). Elevated SIRs were also observed among the following groups: within 1 year after BC diagnosed, a young age at BC diagnosed, black people, poorly or undifferentiated histological grade of breast cancer. Median survival (MST) after localized, regional and distant BC-NSCLC was 68.0, 26.0, and 6.0m. Five-year survival rates for BC-NSCLC were 53.9, 29.8 and 5.7% in each stage, which were significantly higher compared to first primary NSCLC (all p < 0.001). ER-/PR- or TNBC were unfavorable prognostic factors for BC-NSCLC. The survival rates of BC-SCLC were no significant different compared to first primary SCLC. Conclusion: BC patients, especially for TNBC, are at a high risk of developing second primary lung cancers. BC history may be a favorable prognostic factor for NSCLC (but not SCLC) patients. Clinicians should closely follow up BC patients with high-risk factors.

Keywords: SEER; TNBC; breast cancer; lung cancer; population-based study; second primary.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cause of deaths grouped by histology among lung cancer patients who had a history of breast cancer.
Figure 2
Figure 2
Kaplan-Meier overall survivals for BC-NSCLC patients, grouped by ER (A), PR (B), breast cancer types (C) and latency (D) (all p < 0.05).
See this image and copyright information in PMC

References

    1. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. . Effect of screening and adjuvant therapy on mortality from breast cancer. New Engl J Med. (2005) 353:1784–92. 10.1056/NEJMoa050518 - DOI - PubMed
    1. Borgquist S, Hall P, Lipkus I, Garber JE. Towards prevention of breast cancer: what are the clinical challenges? Cancer Prevent Res. (2018) 11:255–64. 10.1158/1940-6207.CAPR-16-0254 - DOI - PubMed
    1. Wang SY, Dang W, Richman I, Mougalian SS, Evans SB, Gross CP. Cost-Effectiveness analyses of the 21-gene assay in breast cancer: systematic review and critical appraisal. J Clin Oncol. (2018) 36:1619–27. 10.1200/JCO.2017.76.5941 - DOI - PMC - PubMed
    1. Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ. Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev. (2007) 16:566–71. 10.1158/1055-9965.EPI-06-0782 - DOI - PubMed
    1. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist (2007) 12:20–37. 10.1634/theoncologist.12-1-20 - DOI - PubMed